BTK Reducing Molecules for Treatment of Cancers and Immune System Disorders
OwnerWei He, Yimin Qian +3inventors
InventorsWei He, Yimin Qian, Feng Chen, Jie Su, Jie Fan
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to methods of treating a disease or disorder associated with dysfunctional phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2), such as cancers and immune system disorders, using Bruton's tyrosine kinase (BTK) reducing molecules, such as BTK degrader molecules.
Claims31
A method of treating a disease or disorder associated with a constitutively activated phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2) in a subject in need thereof, the method comprising administering to the subject an effective amount of a Bruton's tyrosine kinase (BTK) reducing molecule.
A method of treating a disease or disorder associated with a constitutively activated phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2) in a subject in need thereof, the method comprising administering to the subject an effective amount of a Bruton's tyrosine kinase (BTK) reducing molecule, wherein, prior to administering to the subject the BTK reducing molecule, the subject has been identified as having constitutively activated PLCγ2 in one or more cells.
Dependencies are inferred from the claim text.